Click for best price
Neuroblastoma Chemotherapy Drugs Market Size, Share 2023
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
This report aims to provide a comprehensive presentation of the global market for Neuroblastoma Chemotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroblastoma Chemotherapy Drugs. This report contains market size and forecasts of Neuroblastoma Chemotherapy Drugs in global, including the following market information:
Global Neuroblastoma Chemotherapy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Neuroblastoma Chemotherapy Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Neuroblastoma Chemotherapy Drugs companies in 2022 (%)
The global Neuroblastoma Chemotherapy Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Cyclophosphamide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuroblastoma Chemotherapy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuroblastoma Chemotherapy Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, by Type, 2022 (%)
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Global Neuroblastoma Chemotherapy Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Other
Global Neuroblastoma Chemotherapy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuroblastoma Chemotherapy Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neuroblastoma Chemotherapy Drugs revenues share in global market, 2022 (%)
Key companies Neuroblastoma Chemotherapy Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Neuroblastoma Chemotherapy Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuroblastoma Chemotherapy Drugs, market overview.
Chapter 2: Global Neuroblastoma Chemotherapy Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neuroblastoma Chemotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuroblastoma Chemotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neuroblastoma Chemotherapy Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Neuroblastoma Chemotherapy Drugs Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
75 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neuroblastoma Chemotherapy Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuroblastoma Chemotherapy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuroblastoma Chemotherapy Drugs Overall Market Size
2.1 Global Neuroblastoma Chemotherapy Drugs Market Size: 2022 VS 2029
2.2 Global Neuroblastoma Chemotherapy Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Neuroblastoma Chemotherapy Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Neuroblastoma Chemotherapy Drugs Players in Global Market
3.2 Top Global Neuroblastoma Chemotherapy Drugs Companies Ranked by Revenue
3.3 Global Neuroblastoma Chemotherapy Drugs Revenue by Companies
3.4 Global Neuroblastoma Chemotherapy Drugs Sales by Companies
3.5 Global Neuroblastoma Chemotherapy Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neuroblastoma Chemotherapy Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neuroblastoma Chemotherapy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neuroblastoma Chemotherapy Drugs Players in Global Market
3.8.1 List of Global Tier 1 Neuroblastoma Chemotherapy Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Neuroblastoma Chemotherapy Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuroblastoma Chemotherapy Drugs Market Size Markets, 2022 & 2029
4.1.2 Cyclophosphamide
4.1.3 Cisplatin or Carboplatin
4.1.4 Vincristine
4.1.5 Doxorubicin (Adriamycin)
4.1.6 Etoposide
4.1.7 Other
4.2 By Type - Global Neuroblastoma Chemotherapy Drugs Revenue & Forecasts
4.2.1 By Type - Global Neuroblastoma Chemotherapy Drugs Revenue, 2018-2023
4.2.2 By Type - Global Neuroblastoma Chemotherapy Drugs Revenue, 2024-2029
4.2.3 By Type - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Neuroblastoma Chemotherapy Drugs Sales & Forecasts
4.3.1 By Type - Global Neuroblastoma Chemotherapy Drugs Sales, 2018-2023
4.3.2 By Type - Global Neuroblastoma Chemotherapy Drugs Sales, 2024-2029
4.3.3 By Type - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Neuroblastoma Chemotherapy Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuroblastoma Chemotherapy Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Neuroblastoma Chemotherapy Drugs Revenue & Forecasts
5.2.1 By Application - Global Neuroblastoma Chemotherapy Drugs Revenue, 2018-2023
5.2.2 By Application - Global Neuroblastoma Chemotherapy Drugs Revenue, 2024-2029
5.2.3 By Application - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Neuroblastoma Chemotherapy Drugs Sales & Forecasts
5.3.1 By Application - Global Neuroblastoma Chemotherapy Drugs Sales, 2018-2023
5.3.2 By Application - Global Neuroblastoma Chemotherapy Drugs Sales, 2024-2029
5.3.3 By Application - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Neuroblastoma Chemotherapy Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Neuroblastoma Chemotherapy Drugs Market Size, 2022 & 2029
6.2 By Region - Global Neuroblastoma Chemotherapy Drugs Revenue & Forecasts
6.2.1 By Region - Global Neuroblastoma Chemotherapy Drugs Revenue, 2018-2023
6.2.2 By Region - Global Neuroblastoma Chemotherapy Drugs Revenue, 2024-2029
6.2.3 By Region - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Neuroblastoma Chemotherapy Drugs Sales & Forecasts
6.3.1 By Region - Global Neuroblastoma Chemotherapy Drugs Sales, 2018-2023
6.3.2 By Region - Global Neuroblastoma Chemotherapy Drugs Sales, 2024-2029
6.3.3 By Region - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029
6.4.2 By Country - North America Neuroblastoma Chemotherapy Drugs Sales, 2018-2029
6.4.3 US Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.4.4 Canada Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.4.5 Mexico Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Neuroblastoma Chemotherapy Drugs Sales, 2018-2029
6.5.3 Germany Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.4 France Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.5 U.K. Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.6 Italy Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.7 Russia Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.5.9 Benelux Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Neuroblastoma Chemotherapy Drugs Sales, 2018-2029
6.6.3 China Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.6.4 Japan Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.6.5 South Korea Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.6.7 India Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029
6.7.2 By Country - South America Neuroblastoma Chemotherapy Drugs Sales, 2018-2029
6.7.3 Brazil Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.7.4 Argentina Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales, 2018-2029
6.8.3 Turkey Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.8.4 Israel Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
6.8.6 UAE Neuroblastoma Chemotherapy Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Baxter Healthcare
7.1.1 Baxter Healthcare Company Summary
7.1.2 Baxter Healthcare Business Overview
7.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Baxter Healthcare Key News & Latest Developments
7.2 Ingenus Pharmaceuticals
7.2.1 Ingenus Pharmaceuticals Company Summary
7.2.2 Ingenus Pharmaceuticals Business Overview
7.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Ingenus Pharmaceuticals Key News & Latest Developments
7.3 ANI Pharmaceuticals
7.3.1 ANI Pharmaceuticals Company Summary
7.3.2 ANI Pharmaceuticals Business Overview
7.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.3.5 ANI Pharmaceuticals Key News & Latest Developments
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Company Summary
7.4.2 Teva Pharmaceuticals Business Overview
7.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Teva Pharmaceuticals Key News & Latest Developments
7.5 Qilu Pharmaceutical
7.5.1 Qilu Pharmaceutical Company Summary
7.5.2 Qilu Pharmaceutical Business Overview
7.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Qilu Pharmaceutical Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Hikma Pharmaceuticals
7.7.1 Hikma Pharmaceuticals Company Summary
7.7.2 Hikma Pharmaceuticals Business Overview
7.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Hikma Pharmaceuticals Key News & Latest Developments
7.8 Fresenius Kabi
7.8.1 Fresenius Kabi Company Summary
7.8.2 Fresenius Kabi Business Overview
7.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Fresenius Kabi Key News & Latest Developments
7.9 Accord Healthcare
7.9.1 Accord Healthcare Company Summary
7.9.2 Accord Healthcare Business Overview
7.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Accord Healthcare Key News & Latest Developments
7.10 Viatris
7.10.1 Viatris Company Summary
7.10.2 Viatris Business Overview
7.10.3 Viatris Neuroblastoma Chemotherapy Drugs Major Product Offerings
7.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Viatris Key News & Latest Developments
8 Global Neuroblastoma Chemotherapy Drugs Production Capacity, Analysis
8.1 Global Neuroblastoma Chemotherapy Drugs Production Capacity, 2018-2029
8.2 Neuroblastoma Chemotherapy Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Neuroblastoma Chemotherapy Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neuroblastoma Chemotherapy Drugs Supply Chain Analysis
10.1 Neuroblastoma Chemotherapy Drugs Industry Value Chain
10.2 Neuroblastoma Chemotherapy Drugs Upstream Market
10.3 Neuroblastoma Chemotherapy Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neuroblastoma Chemotherapy Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Neuroblastoma Chemotherapy Drugs in Global Market
Table 2. Top Neuroblastoma Chemotherapy Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Neuroblastoma Chemotherapy Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Neuroblastoma Chemotherapy Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Neuroblastoma Chemotherapy Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Neuroblastoma Chemotherapy Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Neuroblastoma Chemotherapy Drugs Product Type
Table 9. List of Global Tier 1 Neuroblastoma Chemotherapy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuroblastoma Chemotherapy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Neuroblastoma Chemotherapy Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Neuroblastoma Chemotherapy Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales, (K Units), 2024-2029
Table 46. Baxter Healthcare Company Summary
Table 47. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Offerings
Table 48. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Baxter Healthcare Key News & Latest Developments
Table 50. Ingenus Pharmaceuticals Company Summary
Table 51. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offerings
Table 52. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Ingenus Pharmaceuticals Key News & Latest Developments
Table 54. ANI Pharmaceuticals Company Summary
Table 55. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offerings
Table 56. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. ANI Pharmaceuticals Key News & Latest Developments
Table 58. Teva Pharmaceuticals Company Summary
Table 59. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offerings
Table 60. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Teva Pharmaceuticals Key News & Latest Developments
Table 62. Qilu Pharmaceutical Company Summary
Table 63. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Offerings
Table 64. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Qilu Pharmaceutical Key News & Latest Developments
Table 66. Pfizer Company Summary
Table 67. Pfizer Neuroblastoma Chemotherapy Drugs Product Offerings
Table 68. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Pfizer Key News & Latest Developments
Table 70. Hikma Pharmaceuticals Company Summary
Table 71. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offerings
Table 72. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Hikma Pharmaceuticals Key News & Latest Developments
Table 74. Fresenius Kabi Company Summary
Table 75. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Offerings
Table 76. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Fresenius Kabi Key News & Latest Developments
Table 78. Accord Healthcare Company Summary
Table 79. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Offerings
Table 80. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Accord Healthcare Key News & Latest Developments
Table 82. Viatris Company Summary
Table 83. Viatris Neuroblastoma Chemotherapy Drugs Product Offerings
Table 84. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Viatris Key News & Latest Developments
Table 86. Neuroblastoma Chemotherapy Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Neuroblastoma Chemotherapy Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Neuroblastoma Chemotherapy Drugs Production by Region, 2018-2023 (K Units)
Table 89. Global Neuroblastoma Chemotherapy Drugs Production by Region, 2024-2029 (K Units)
Table 90. Neuroblastoma Chemotherapy Drugs Market Opportunities & Trends in Global Market
Table 91. Neuroblastoma Chemotherapy Drugs Market Drivers in Global Market
Table 92. Neuroblastoma Chemotherapy Drugs Market Restraints in Global Market
Table 93. Neuroblastoma Chemotherapy Drugs Raw Materials
Table 94. Neuroblastoma Chemotherapy Drugs Raw Materials Suppliers in Global Market
Table 95. Typical Neuroblastoma Chemotherapy Drugs Downstream
Table 96. Neuroblastoma Chemotherapy Drugs Downstream Clients in Global Market
Table 97. Neuroblastoma Chemotherapy Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Neuroblastoma Chemotherapy Drugs Segment by Type in 2022
Figure 2. Neuroblastoma Chemotherapy Drugs Segment by Application in 2022
Figure 3. Global Neuroblastoma Chemotherapy Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neuroblastoma Chemotherapy Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Neuroblastoma Chemotherapy Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Neuroblastoma Chemotherapy Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Neuroblastoma Chemotherapy Drugs Revenue in 2022
Figure 9. By Type - Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Neuroblastoma Chemotherapy Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 23. US Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 28. Germany Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 37. China Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Neuroblastoma Chemotherapy Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Neuroblastoma Chemotherapy Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Neuroblastoma Chemotherapy Drugs by Region, 2022 VS 2029
Figure 54. Neuroblastoma Chemotherapy Drugs Industry Value Chain
Figure 55. Marketing Channels
